SIRT1 and metabolic dysfunction-associated steatotic liver disease: Accordingly, by targeting the hepatic SIRT1-SREBP1c pathway, the SIRT1 chemical activator resveratrol (50 mg/kg/day) was able to reduce the increased susceptibility to diet-induced NAFLD by reversing the intrauterine programming of hepatic lipogenesis after birth in PEE offspring rats [149].